Insider filing · ZIVO

Mark E Strome bought $1.5M of Zivo Bioscience (ZIVO)

Executed Dec 26 2024, disclosed Dec 31 2024, 5 days later, against a two-business-day limit.

Over the 21 trading sessions from the disclosed entry session (Dec 31 2024), the stock returned +7.3% (delay-adjusted); from the execution session (Dec 26 2024), -5.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

MS Mark E Strome Director profile →

Mark E Strome (Director) filed 5 Form 4 reports in the trailing twelve months (4 purchases, 1 sale, 3 filed past the two-business-day deadline), most often in ZIVO. Across 4 priced purchase filings, the average 21-session return was +20.4% from execution and +58.0% from disclosure (delay-adjusted; derived). The largest single filing was $895K of BEAT (250,000 sh × $3.58, as filed), executed Dec 17 2025.

ZIVO ZIVO ZIVO · 7 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→